Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
doi: https://doi.org/10.1101/2020.12.20.20248602
Shilong Yang
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Li
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianpan Dai
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianfeng Wang
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peng He
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changgui Li
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Fang
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chenfei Wang
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang Zhao
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enqi Huang
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changwei Wu
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaixin Zhong
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fengze Wang
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaomin Duan
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siyu Tian
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lili Wu
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Liu
10Chongqing Medleader Bio-Pharm Co. Ltd., Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Luo
9Beijing Keytech Statistical Technology Co. Ltd., Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhihai Chen
8Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fangjun Li
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junhua Li
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xian Yu
6The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Ren
6The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihong Liu
7Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shufang Meng
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gaof@im.ac.cn gldlj@hotmail.com huzhy@nifdc.org.cn yanjh@im.ac.cn mengsf@263.net
Jinghua Yan
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gaof@im.ac.cn gldlj@hotmail.com huzhy@nifdc.org.cn yanjh@im.ac.cn mengsf@263.net
Zhongyu Hu
4National Institute for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gaof@im.ac.cn gldlj@hotmail.com huzhy@nifdc.org.cn yanjh@im.ac.cn mengsf@263.net
Lidong Gao
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gaof@im.ac.cn gldlj@hotmail.com huzhy@nifdc.org.cn yanjh@im.ac.cn mengsf@263.net
George F. Gao
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gaof@im.ac.cn gldlj@hotmail.com huzhy@nifdc.org.cn yanjh@im.ac.cn mengsf@263.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background A safe and effective coronavirus disease 2019 (COVID-19) vaccine is urgently needed to control the ongoing pandemic. Although progress has been made recently with several candidates reporting positive efficacy results, COVID-19 vaccines developed so far cannot meet the global vaccine demand. We developed a protein subunit vaccine against COVID-19, using dimeric form of receptor-binding domain (RBD) as the antigen. We aimed to assess the safety and immunogenicity of this vaccine in humans and determine the appropriate dose and schedule for an efficacy study.

Methods We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults aged 18-59 years were enrolled and randomly allocated to three groups to receive three doses of vaccine (25 μg or 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59 years were enrolled and randomly allocated to six groups to receive vaccine (25 μg or 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the former 3 groups given two doses and the latter 3 groups given three doses, 30 days apart. For phase 1 trial, the primary outcome was safety, as measured by the occurrence of adverse events and serious adverse events. The secondary outcome was immunogenicity as measured by the seroconversion rate and magnitude of antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For phase 2 trial, the primary outcome included both safety and immunogenicity. These trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085.

Findings Between June 22 and September 15, 2020, 50 participants were enrolled to the phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or three-dose schedule. For both trials, local and systemic adverse reactions were absent or mild in most participants. There were no serious adverse events related to vaccine in either trial. After three doses, neutralizing antibodies were detected in all participants receiving either 25 μg or 50 μg dose of vaccine in phase 1 study, and in 97% (the 25 μg group) and 93% (the 50 μg group) of participants, respectively, in phase 2 study. The SARS-CoV-2-neutralizing geometric mean titres (GMTs) were 94.5 for the 25 μg group and 117.8 for the 50 μg group in phase 1, and 102.5 for the 25 μg group and 69.1 for the 50 μg group in phase 2, exceeding the level of a panel of COVID-19 convalescent samples (GMT, 51). Vaccine induced balanced TH1 and TH2 responses. The 50 μg group did not show enhanced immunogenicity compared with the 25 μg group.

Interpretation The protein subunit vaccine ZF2001 is well-tolerated and immunogenic. The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 μg vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy.

Funding National Program on Key Research Project of China, National Science and Technology Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical.

Competing Interest Statement

SY, EH, CW, and ZZ are employees of Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. YL (Yan Liu) is an employee of Chongqing Medleader Bio-Pharm Co. Ltd. YL (Yi Luo) is an employee of Beijing Keytech Statistical Technology Co. Ltd. LD, YL, JY and GFG are listed as inventors on pending patent applications for RBD- dimer- based CoV vaccines. The pending patents for RBD- dimers as protein subunit vaccines for SARS- CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.

Clinical Trial

NCT04445194, NCT04466085

Funding Statement

This work is funded by National Program on Key Research Project of China (2020YFC0842300), National Science and Technology Major Projects of Drug Discovery (2018ZX09101001), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010202) and Anhui Zhifei Longcom Biopharmaceutical.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by the institutional review board of The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao-Yang Hospital of Capital Medical University, Hunan Provincial Center for Disease Control, Prevention and National Medical Products Administration (NMPA), China and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Individual participant data will be made available on request, directed to the corresponding author (GFG). After approval of a proposal, data can be shared through a secure online platform.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
medRxiv 2020.12.20.20248602; doi: https://doi.org/10.1101/2020.12.20.20248602
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
medRxiv 2020.12.20.20248602; doi: https://doi.org/10.1101/2020.12.20.20248602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9774)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)